V. Frodermann
PhD candidate / guest
- Name
- Dr. V. Frodermann
- Telephone
- +31 71 527 6213
- v.frodermann@lacdr.leidenuniv.nl
PhD candidate / guest
- Science
- Leiden Academic Centre for Drug Research
- LACDR/Biopharmaceutics
- Hoekstra M., Ren B., Laurila P.P., Hildebrand R.B., Soronen J., Frodermann V., Li Z., Boon M.R., Geerling J.J., Rensen P.C.N., Jauhiainen M. & Eck M. van (2021), Hematopoietic upstream stimulating factor 1 deficiency is associated with increased atherosclerosis susceptibility in LDL receptor knockout mice, Scientific Reports 11: 16419.
- Foks A.C., Puijvelde G.H.M. van, Wolbert J., Kröner M.J., Frodermann V., Heijden T. van der, Santbrink P.J. van, Boon L., Bot I. & Kuiper J. (2016), CD11b+Gr-1+ myeloid-derived suppressor cells reduce atherosclerotic lesion development in LDLr deficient mice, Cardiovascular Research 111(3): 252-261.
- Schaftenaar F., Frodermann V., Kuiper J. & Lutgens E. (2016), Atherosclerosis: the interplay between lipids and immune cells, Current Opinion in Lipidology 27(3): 209-215.
- Frodermann V., Duijn J. van, Pel M. van, Santbrink P.J. van, Bot I., Kuiper J. & Jager S.C. de (2015), Mesenchymal Stem Cells Reduce Murine Atherosclerosis Development, Scientific Reports 5: 15559.
- Frodermann V. (27 May 2015), Novel immune cell-based therapies for atherosclerosis (Dissertatie, Faculty of Science, Leiden University). Supervisor(s) and Co-supervisor(s): Kuiper J., Jager S.C.A. de.
- Foks A.C., Bot I., Frodermann V., Jager S.C.A. de, Borg M. ter, Santbrink P.J. van, Yagita H., Kuiper J. & Puijvelde G.H.M. van (2012), Interference of the CD30-CD30L pathway reduces atherosclerosis development, Immunology 137: 478-478.
No relevant ancillary activities